Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Erasmus Medical Center | OTHER |
Not provided
Not provided
Not provided
Not provided
Postprandial hyperinsulinaemic hypoglycaemia is an increasingly recognized adverse side effect of bariatric surgery. Affected individuals experience low glucose levels 1-3 hours after intake of meals, accompanied by symptoms such as drowsiness, sweating, hunger and palpitations. Hypoglycaemia can be serious and have potential dangerous health impact (e.g. road accident or fall due to loss of consciousness). The pathophysiology is incompletely understood and more research is needed in search of preventive and therapeutic strategies.
Obesity is a major global health concern that is associated with significant disability and mortality. Worldwide, the prevalence of obesity has doubled since 1980, affecting 13% of the global population. Bariatric surgery has been shown to be the most effective and durable treatment of severe obesity and leads to significant improvement of obesity-related comorbidity. However, postprandial hyperinsulinaemic hypoglycaemia (PHH) after bariatric surgery is a metabolic complication that is increasingly being recognized. Prevalence rates of up to 72% have been reported. PHH may have serious implications for affected patients, including negative effects on morbidity, mortality as well as quality of life. The pathophysiology of PPH is incompletely understood and suggests decreased adaptation of beta cell function to increased insulin sensitivity. The latter has been postulated to be largely secondary due to external factors outside the beta cells as a result of anatomical and hormonal changes after Roux-en-Y gastric bypass (RYGB). However, the intrinsic mechanistic effects of altered beta-cell function after RYGB in vivo are unknown and more exploration could lead to a better understanding of PHH pathogenesis and help identify targets for possible interventions. Previous studies performed enhanced beta cell analysis by following insulin synthesis in real-time based on stable isotope labelling of C-peptide during an oral glucose tolerance test (OGTT) in cohorts with normal and diabetic glucose tolerance. Applying the same methodological approach, albeit in a different target population (PPH after bariatric surgery), the present study seeks to explore whether or not the insulin hypersecretion can be explained by an increase in insulin synthesis, and secondly, whether potentially increased insulin synthesis can be related to other glucoregulatory hormones and measures of insulin sensitivity.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| OGTT with 13C-labelled leucine | Experimental | Intake of 75g of glucose with 1g of 13C leucine pre-feeding |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Dietary Supplement: Glucose | Other | Intake of 75g of glucose with 1g of 13C leucine pre-feeding |
|
| Measure | Description | Time Frame |
|---|---|---|
| Fractional synthesis rate of de novo C-peptide synthesis (%/hr) | Calculated | 4.5 hours |
| Measure | Description | Time Frame |
|---|---|---|
| C-peptide levels in blood | Measured | 4.5 hours |
| Insulin levels in blood | Measured | 4.5 hours |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Christoph Stettler, MD | Inselspital, Bern University Hospital, University of Bern | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Division of Endocrinology, Diabetes and Clinical Nutrition, Bern University Hospital | Bern | 3010 | Switzerland |
Not provided
| ID | Term |
|---|---|
| D007003 | Hypoglycemia |
| D007333 | Insulin Resistance |
| ID | Term |
|---|---|
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D006946 | Hyperinsulinism |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Glucagon levels in blood | Measured | 4.5 hours |
| Incretin levels in blood | Measured | 4.5 hours |
| Insulin sensitivity | Calculated | 4.5 hours |
| Beta cell responsivity | Calculated | 4.5 hours |
| Hepatic insulin extraction | Calculated | 4.5 hours |
| C-peptide levels in urine | Measured | 4.5 hours |
| C-peptide enrichment | calculated | 4.5 hours |